Who are Levodopa/carbidopa/entacapone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): sinemet plus.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levodopa-carbidopa-entacapone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Levodopa/carbidopa/entacapone — Competitive Intelligence Brief

Levodopa/carbidopa/entacapone (Levodopa/carbidopa/entacapone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine precursor with decarboxylase inhibitor and COMT inhibitor. Area: Neurology.

marketed Dopamine precursor with decarboxylase inhibitor and COMT inhibitor Dopamine pathway; COMT enzyme Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Levodopa/carbidopa/entacapone (Levodopa/carbidopa/entacapone) — Novartis. Levodopa is converted to dopamine in the brain to restore dopamine levels, while carbidopa blocks its peripheral conversion and entacapone inhibits catechol-O-methyltransferase to extend levodopa's duration of action.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levodopa/carbidopa/entacapone TARGET	Levodopa/carbidopa/entacapone	Novartis	marketed	Dopamine precursor with decarboxylase inhibitor and COMT inhibitor	Dopamine pathway; COMT enzyme
sinemet plus	sinemet plus	Hospital de Granollers	marketed	Dopamine replacement therapy with COMT inhibitor	Dopamine pathway; COMT enzyme

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine precursor with decarboxylase inhibitor and COMT inhibitor class)

Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levodopa/carbidopa/entacapone — Competitive Intelligence Brief. https://druglandscape.com/ci/levodopa-carbidopa-entacapone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab